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Hyperfunctioning nodules of the thyroid are thought to only rarely harbor thyroid cancer, and thus are infrequently
biopsied. Here, we present the case of a patient with a hyperfunctioning thyroid nodule harboring thyroid
carcinoma and, using MEDLINE literature searches, set out to determine the prevalence of and characteristics of
malignant “hot” nodules as a group. Historical, biochemical and radiologic characteristics of the case subjects and
their nodules were compared to those in cases of benign hyperfunctioning nodules. A literature review of surgical
patients with solitary hyperfunctioning thyroid nodules managed by thyroid resection revealed an estimated 3.1%
prevalence of malignancy. A separate literature search uncovered 76 cases of reported malignant hot thyroid
nodules, besides the present case. Of these, 78% were female and mean age at time of diagnosis was 47 years.
Mean nodule size was 4.13 ± 1.68 cm. Laboratory assessment revealed T3 elevation in 76.5%, T4 elevation in 51.9%,
and subclinical hyperthyroidism in 13% of patients. Histological diagnosis was papillary thyroid carcinoma (PTC) in
57.1%, follicular thyroid carcinoma (FTC) in 36.4%, and Hurthle cell carcinoma in 7.8% of patients. Thus, hot thyroid
nodules harbor a low but non-trivial rate of malignancy. Compared to individuals with benign hyperfunctioning
thyroid nodules, those with malignant hyperfunctioning nodules are younger and more predominantly female.
Also, FTC and Hurthle cell carcinoma are found more frequently in hot nodules than in general. We were unable to
find any specific characteristics that could be used to distinguish between malignant and benign hot nodules.
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Thyroid nodules are frequently-encountered entities in
clinical practice, occurring with a prevalence of 4% by
palpation [1], 33% to 68% by ultrasound examination
[2,3], and 50% on autopsy series [4]. While approxi-
mately 95% of thyroid nodules are benign, certain his-
torical, laboratory, and sonographic features raise the
suspicion for malignancy [5]. As the initial step for
evaluation of a thyroid nodule is measurement of serum
thyroid stimulating hormone (TSH) [6,7], it is not un-
common for patients with a solitary thyroid nodule to
be diagnosed with hyperthyroidism. In this setting, the
thyroid nodule may represent a solitary hyperfunctioning* Correspondence: jeffrey.zigman@utsouthwestern.edu
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distribution, and reproduction in any mediumthyroid nodule in an otherwise normal thyroid gland or
it may represent a hyperfunctioning or nonfunctioning
nodule occurring within a toxic multinodular goiter,
within a Graves’ disease or destructive thyroiditis milieu,
or in an individual with a less common cause of thyro-
toxicosis [8]. Thyroid scintigraphy employs radioiodine
(123I, 131I) or technetium-99m-(99mTc) pertechnetate in
order to differentiate these diagnostic possibilities. The
distinction is important, because hyperfunctioning nod-
ules – also referred to as “autonomous,” “autonomously-
functioning,” or “hot” nodules – are thought to only
rarely harbor malignancy, such that fine needle aspiration
(FNA) is not traditionally indicated in this circumstance
[6]. Per the 2009 revised American Thyroid Association
Management Guidelines for Patients with Thyroid No-
dules and Differentiated Thyroid Cancer, “Since hyper-
functioning nodules rarely harbor malignancy, if one isntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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logic evaluation is necessary” [6].
Here, we present the case of a woman with subclinical
hyperthyroidism due to a hyperfunctioning thyroid nodule
who was diagnosed with minimally-invasive follicular car-
cinoma after surgical resection. We also include our find-
ings from a formal literature review on this topic, in which
the historical, laboratory, and radiological features of
similarly-documented cases were scrutinized to determine
if there are features that differentiate hyperfunctioning
thyroid carcinomas from solitary toxic adenomas. The re-
sults of a separate literature review aimed at estimating
the prevalence of thyroid cancer within hot thyroid nod-
ules are also presented. Our goal is to call attention to the
fact that hyperfunctioning thyroid carcinomas are well-
described in the literature (and also likely underreported),
challenging the commonly-held notion that the hot thy-
roid nodule is very unlikely to be cancerous.
Materials and methods
A MEDLINE literature search of English-language stu-
dies published between 1950 and January 2012 with
the terms, “thyroid cancer, hyperthyroidism, surgery,”
“thyroid cancer, hyperfunctioning nodule, surgery,” and
“thyroid cancer, hot nodule, surgery,” was performed to
determine the reported prevalence of thyroid carcinoma
in patients undergoing resection of solitary hyperfunc-
tioning thyroid nodules. Another literature search, using
the terms, “hyperfunctioning thyroid carcinoma,” “toxic
adenoma, thyroid carcinoma,” and “hot nodule, thyroid
carcinoma” was performed using MEDLINE and by re-
viewing the citations of relevant articles in order to col-
lect data on reported cases of patients with a solitary
thyroid nodule found to harbor thyroid carcinoma. Case
series were included provided that at least some demo-
graphic and clinical details of individual subjects were
described. A third MEDLINE literature search, using the
terms “hot nodule,” “hyperfunctioning thyroid nodule,”
and “autonomous thyroid nodules,” was performed to
establish the demographic characteristics and nodule
sizes of subjects with solitary hyperfunctioning thyroid
nodules. In this third group, the available studies ana-
lyzed the group of hyperfunctioning nodules en masse
and did not make a distinction between hyperfunc-
tioning nodules that were benign and those that may
have been malignant. Therefore, while the aggregate data
from these studies most likely involved predominantly
benign cases, a small number of malignant cases also
may have been included. For this reason, we will subse-
quently refer to this group as “predominantly-benign”
hyperfunctioning (or hot) nodules.
Weighted averages of data were calculated by assig-
ning a “weight” to each study (based on the number of
subjects in the study divided by the total number ofsubjects for all studies), multiplying each weight by the
subject mean in the corresponding study, and then tak-
ing the sum of these products.
Results
Patient case
A 29-year-old teacher was referred to her local endo-
crinologist to evaluate a palpable left thyroid nodule.
While she did not report thyrotoxic symptoms at that
time, she was found to have a suppressed TSH. Thyroid
scintigraphy revealed a hyperfunctioning left-sided thyroid
nodule, and ultrasonography revealed it to be 2.4 cm in
greatest dimension, isoechoic, and in the left lower lobe. A
follow-up ultrasound one year later revealed an essentially
unchanged nodule measuring 2.5 cm.
The patient presented to our institution the next year,
at which time she endorsed tremors, anxiety, insomnia,
and oligomenorrhea. She denied local compressive symp-
toms, history of radiation exposure, or family history of
thyroid malignancy. Her only medication was a daily
multivitamin. Her weight was 106 kg with a height of 1.7
m, blood pressure of 117/73 mmHg, and heart rate of 79
beats per minute. A 1.5 cm, firm, slightly tender nodule
was palpated in the left lower lobe of the thyroid; it moved
with swallowing. There was no evidence of cervical
lymphadenopathy or thyroid bruit. The patient had a
slight, fine tremor of the hands with normal biceps deep-
tendon reflexes bilaterally.
Thyroid function tests revealed a suppressed TSH
(0.005 mcIU/mL, normal 0.4 - 4.5 mcIU/mL) but normal
free T4 (1.1 ng/dL, normal 0.9 - 1.8 ng/dL) and free T3
(3.5 pg/mL, normal 2.3 - 4.2 pg/mL). Thyroid peroxidase
antibody testing was negative (0.4 IU/mL, normal < 9
IU/mL), as were thyroglobulin antibody (< 20 IU/mL) and
thyroid stimulating immunoglobulin (< 1.0) testing. Thy-
roid ultrasound revealed a 2.6 × 2.7 × 2.6 cm predomin-
antly solid, isoechoic left lower lobe nodule with internal
hypervascularity within a slightly enlarged but otherwise
normal-appearing thyroid gland (Figure 1A and B). 123I
thyroid scintigraphy revealed a left lower lobe hyperfunc-
tioning nodule with 24-hour uptake of 27% (Figure 1C).
After discussing with the patient the benefits and risks
of radioiodine ablation versus surgical resection (left
hemithyroidectomy), she elected for the latter, citing the
reduced risk of permanent hypothyroidism as her main
deciding factor. Histologic evaluation of the surgical
specimen revealed a solitary, circumscribed, and well-
encapsulated tumor measuring 2.5 × 2.5 × 2.2 cm with-
out lymphovascular invasion or extra-thyroidal extension
(Figure 1D). A focus was identified where the tumor pene-
trated and budded through the well-defined fibrous cap-
sule, giving the diagnosis of minimally-invasive follicular
thyroid carcinoma (Figure 1E) in the setting of back-
ground lymphocytic thyroiditis. Given the pathologic
Figure 1 Imaging and histologic features of the hot nodule present in the case report subject. (A) Ultrasonography of the left thyroid
lobe, demonstrating a 2.7 cm, predominantly solid, and isoechoic nodule. (B) Color Doppler evaluation reveals blood flow within the rim of the
nodule and intraparenchymally. (C) 123I thyroid scintigram depicts a round left-sided focus of iodine uptake with suppression in the remainder of
the gland, consistent with an autonomously-functioning thyroid nodule. (D) Histological evaluation reveals that the lesion is solitary, circumscribed
and encapsulated. The follicular proliferation is surrounded by a rather thick fibrous capsule. The lesion demonstrates a predominant follicular pattern
of growth without papillary cytologic features (hematoxylin-eosin stain; original magnification × 4). (E) A focal area is identified where the tumor
invades through and into the fibrous capsule (hematoxylin-eosin stain; original magnification × 2).
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completion thyroidectomy nor radioactive iodine ablation
was pursued in this patient. Molecular testing was per-
formed on the surgical specimen for BRAF and KRAS
mutations, both of which were negative. At her 6-month
follow up appointment, the patient was symptomatically
and biochemically euthyroid on low-dose levothyroxine re-
placement and showed no evidence of cancer recurrence.
Estimated prevalence of malignancy within hot thyroid
nodules
In order to place the current case report in context, we
have attempted to establish the prevalence of malignancy
within hot thyroid nodules. This involved a literature
search for surgical case series of solitary hyperfunc-
tioning nodules managed by thyroid resection. A total of14 relevant case series were uncovered. The earliest we
found was from 1967 and included 79 hot nodules that
underwent surgical resection; none of those cases were
found to harbor thyroid carcinoma. Among the 14 case
series, carcinoma rates of intranodular carcinoma ran-
ging from 0 – 12.5% were noted, with a weighted total
of 3.1% (Table 1). Of note, some of those case series also
included cases in which thyroid carcinoma occurred out-
side of the hot nodule; however for the purposes of our
review, such extranodular cases were not included in
our estimated prevalence determination.
Search for distinctive features of malignant hot thyroid
nodules
We next sought to establish historical and/or clinical
features that may help to differentiate malignant,
Table 1 Intranodular thyroid carcinoma prevalence in













Giles [9] 176 4 2.3
Cakir [10] 63 4 6.3
Cappelli [11] 207 3 1.4
Foppiani [12] 16 2 12.5
Sahin [13] 77 2 2.6
Gabriele [14] 120 2 1.7
Harach [15] 73 6 8.2
Vaiana [16] 153 3 2
Zanella [17] 41 3 7.3
Terzioglu [18] 25 2 8
Pacini [19] 40 1 2.5




Horst [22] 79 0 0
Total 1124 35 3.1
Only cases of intra-nodular malignancy are included. Studies are arranged in
order of ascending date of publication.
n = number of case.
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enomas, especially since hyperfunctioning thyroid carcin-
oma is generally an ex post facto diagnosis. Using the
search criteria listed in the Methods Section, we discov-
ered 76 cases (in addition to the current case) of malig-
nant hot thyroid nodules, in which autonomy was highly
suggested by both biochemical parameters of hyperthy-
roidism and scintigraphic evidence of increased radioio-
dine or labeled technetium uptake. All possibly-relevant
features of the 77 cases were extracted and are displayed
in Table 2, and a further analysis of these features appears
in Table 3. An additional 27 cases with scintigraphic evi-
dence suggestive of nodular autonomy but with normal
thyroid function tests, absent thyroid function testing, or
uninterpretable laboratory results (e.g., patients already on
levothyroxine therapy at time of laboratory collection)
were also found in the literature search (Table 4); these
cases were excluded from subsequent analyses since au-
tonomy seemed less certain.
Demographic characteristics
We compared age at diagnosis and female: male ratio of
individuals with malignant, hyperfunctioning thyroid
nodules to those with benign, toxic adenomas. Data on
the latter group was compiled from a separate literature
search which identified several surgical case series ofpredominantly-benign hot nodules, as described in the
Methods section (Table 5). Subjects with malignant hot
nodules were younger at the time of diagnosis than those
listed in multiple case series of predominantly-benign hot
nodules [47.0 vs. 57.6 years, respectively (Tables 3 and 5)].
Additionally, a greater percentage of subjects with malig-
nant hot nodule were female as compared to those with
predominantly-benign hot nodules [3.53:1 vs. 1.65:1 fe-
male to male ratio, respectively (Tables 3 and 5)].
Size
The sizes of the malignant hot nodules (Table 2) and
predominantly-benign hot thyroid nodules are compared
in Figure 2A. Of note, the clinical use of ultrasonography
began in the late 1960s, so that the sizes listed in the
early case reports of malignant hot nodule were esti-
mated by palpation. We include tumors that were noted
to encompass the entirety of the hot nodule as well as
microcarcinomas embedded within a larger hot nodule.
The actual size of the tumor within the thyroid nodule
determined by pathological review was occasionally pro-
vided in the literature and is listed in Tables 2 and 4.
The mean nodule size among the subjects with thyroid
carcinoma was 4.13 ± 1.68 cm, which closely approxi-
mates the mean size of the predominantly-benign hy-
perfunctioning nodules.
Biochemical profile
The majority of subjects with a malignant hot no-
dule demonstrated elevation of triiodothyronine (76.5%),
whereas closer to half of the subjects had elevation of
thyroxine (51.9%) (Table 3). Note that these percentages
represent the number of subjects with an elevated thy-
roid hormone level (total and/or free value, depending
on the particular study) divided by the total number
of subjects with a hyperfunctioning thyroid nodule. Far
fewer subjects had subclinical hyperthyroidism (13%)
(Table 3). In comparison, with the exception of 3 studies,
similar data on the biochemical profiles of subjects with
benign, toxic adenoma in the collected case series were
only sparsely included. In a study of 35 subjects with
toxic adenoma, Hamburger found 16 with elevations in
both T3 and T4 levels, 16 with elevations of only T3, 3
with isolated T4 excess, and 7 with subclinical hyperthy-
roidism [77]. In a study of 63 patients with solitary toxic
adenoma, Langer found that mean free T3 level was sig-
nificantly higher (8.8 ± 3.5 pg/mL, normal range 4 – 6.8
pg/mL) than mean free T4 level (16.9 ± 6.6 pg/mL, nor-
mal range 7 – 17.5 pg/mL) [78]. Blum evaluated 35 pa-
tients with solitary autonomous thyroid nodule and
found that 65% had elevated T3 levels, 54 % had elevated
T4 levels, and 31% were biochemically euthyroid [72].
Thus, hypersecretion of T3 appears to be a common fac-
tor among both benign and malignant hyperfunctioning
Table 2 Reported cases of biochemically-hyperthyroid patients with a reported hyperfunctioning nodule discovered to harbor thyroid carcinoma on
pathological review
# Age Sex Tumor growth
(cm)














1 29 F - IV 2.7 2.5 SHT + - 123I FTC Current case
2 43 F - - 6.5 5 fT3,fT4 + - Tc Hurthle Karanchi [23]
3 13 F - IV 3.5 5 TT3 - -
123I Hurthle Yalla [24]




5 68 F - HE 5.3 fT3 + + Tc,
123I FTC Giovanella [26]
6 11 F - - 3.5 TT3 - -
123I Nonspecific PTC Tfayli [27]
7 47 F - - 2.6 3 TT3,fT4 + -
131I PTC FVPTC Azevedo [28]
8 36 M 1.4→1.8 in 11mo - HE,IV 1.8 1.5 SHT + - 131I PTC PTC Uludag [29]
9 62 F - 2 fT3,fT4 + - Tc PTC PTC Nishida [30]
10 32 M - - 4.3 fT3,fT4 - - Tc Benign FVPTC Kim [31]
11 64 F - 6 TT3 + -
131I FTC Niepomniszcze [32]
12 57 F - 6 Highf + - Tc Nondiagnostic FTC Bitterman [33]
13 59 F - 5 High + Tc FTC Bitterman [33]
14 59 F - HE,PD,Cal 1.5 1.5 fT3,fT4 + + Tc,
123I PTC PTC Majima [34]
15 NA F 5 5 fT3,fT4 + + Tc PTC Gozu [35]
16 67 F 2.5 3 fT4 + - Tc Benign Hurthle Wong [36]
17 39 F Subjective ↑ - 2 Nl→SHT - - → + 123I PTC Yaturu [37]
18 36 M 2x size in 5yrs - 2.8 2.3 SHT - Follicular
neoplasm
FVPTC Logani [38]
19 11 F - - 4 TT3,fT4 + - Tc,
131I PTC Mircescu [39]
20 49 F 4 3.5 fT4 + -
123I FTC Camacho [40]
21 47 M 3.5 3.5 fT3 +
123I Suspicious PTC Bourasseau [41]
22 36 M 2.5 2.5 SHT 123I Nondiagnostic FTC Bourasseau [41]
23 56 M 5.5 5.5 fT4 +
123I FTC Bourasseau [41]
24 39 F 1 1 fT3,fT4 +
123I Suspicious PTC Bourasseau [41]
25 33 F 3 3 SHT 123I Nondiagnostic PTC Bourasseau [41]
26 42 F 4.5→7.4
(no interval given)
- - 7.4 SHT - - 123I Benign Hurthle Russo [42]
27 17 F - HE 2.1 2.1 TT3 - - Tc,
123I PTC Cirillo [43]
28 60 F - 5 6 TT3 + -
131I Insular Russo [44]
29 16 F - 2 TT4 + -
















Table 2 Reported cases of biochemically-hyperthyroid patients with a reported hyperfunctioning nodule discovered to harbor thyroid carcinoma on
pathological review (Continued)
30 64 F 4 High 123I FTC Mizukami [46]
31 25 F - - 4.2 TT3,TT4 + +
131I PTC/FTC De Rosa [47]
32 72 M 2.8 TT3,TT4 Tc PTC Ikekubo [48]
33 52 M 5 TT3 Tc PTC Ikekubo [48]
34 55 F 1.6 SHT Tc PTC Ikekubo [48]
35 67 F - 3 2.5 TT3,fT4 + -
123I Malignant node PTC Sandler [49]
36 11 F - - 3.5 TT3 + -
123I FTC Nagai [50]
37 45 F - 3.5 3 High + - 123I FVPTC Nagai [50]
38 70 F - 4 4 fT4 - - 131I PTC PTC Fukata [51]
39 27 F - 3 TT4 +
131I PTC Sobel [52]
40 14 M 4 TT3 + -
131I PTC Sobel [52]
41 32 F - 2.5 TT4 +
131I FVPTC Sobel [52]
42 29 F - 1 TT4 + -
131I PTC Hoving [53]
43 44 F irregular 2.5 0.3 TT4 + -
131I PTC Khan [54]
44 15 F 2.5 2.5 TT3 + -
123I PTC Hopwood [55]
45 6 F ↑ over 8mo - 5-6x nl High + - 131I PTC/FTC Sussman [56]
46 42 F 4→6 in 4 yrs 6 6 High - FTC Dische [57]
47 71 F fT3,fT4
131I FTC Als [58]
48 62 M 8 fT3
131I FTC Als [58]
49 62 F 7 fT3
131I FTC Als [58]
50 71 F 4 fT3,fT4
131I FTC Als [58]
51 69 F 6 fT3
131I FTC Als [58]
52 79 F fT3,fT4
131I FTC Als [58]
53 65 M 6.5 fT3
131I FTC Als [58]
54 56 M fT3
131I FVPTC Als [58]
55 75 M 5.5 fT3
131I FTC Als [58]
56 77 F 4 fT3
131I PTC Als [58]
57 71 F 6 fT3
131I FVC Als [58]
58 63 M 6 fT3
131I FVPTC Als [58]
59 74 F 7 fT3,fT4
131I FTC Als [58]


















Table 2 Reported cases of biochemically-hyperthyroid patients with a reported hyperfunctioning nodule discovered to harbor thyroid carcinoma on
pathological review (Continued)
61 38 F HE 2.7 SHT Tc Hyperplastic
goiter
FTC Foppiani [12]
62 35 F - >1cm High + 131I PTC PTC Sahin [13]
63 65 F - >1cm High + 131I PTC PTC Sahin [13]
64 19 F 5 TT4,TT3 PTC Lin [59]
65 38 F - - 0.3 TT3 +
131I no malignancy PTC Taneri [60]
66 44 F - Cal 1 TT3 +
131I no malignancy PTC Taneri [60]
67 56 F - 0.8 High 131I FTC Gabriele [14]
68 21 F - IV 1.6 High 131I FTC Gabriele [14]
69 57 F - - 0.7 High PTC Vaiana [16]
70 58 F - - 3 High PTC Vaiana [16]
71 51 F - - 0.6 High PTC Vaiana [16]
72 17 F - 1 High + PTC Pacini [19]
73 65 F Subjective ↑ 5 High + FTC Terzioglu [18]
74 42 F High + PTC Terzioglu [18]
75 35 F - 2.2 0.5 High PTC Zanella [17]
76 70 F - 4.1 0.5 High PTC Zanella [17]
77 35 M - 5.4 0.5 High Hurthle Zanella [17]
Abbreviations: + = yes; - = no; Cal = microcalcifications; FNA = fine needle aspiration; FTC = follicular thyroid carcinoma; FVPTC = follicular variant of papillary thyroid carcinoma; HE = hypoechoic; 123I = Iodine-123; 131I
= Iodine-131; IV = internal vascularity; LT4 = levothyroxine; NA = not available; nl = normal; PD = poorly demarcated; PTC = papillary thyroid carcinoma; sx = symptoms; SHT = subclinical hyperthyroidism; fT3 = free
triiodothyronine; fT4 = free thyroxine; TT3 = total triiodothyronine; TT4 = total thyroxine;
99mTc = technetium-99m-pertechnetate; TFTs = thyroid function testing; U/S = ultrasound; XRT = external beam radiotherapy.
a High-risk history: ionizing radiation exposure as child/adolescent, prior personal history of thyroid cancer, and family history of thyroid cancer in one or more 1st-degree relatives; as per Cooper et al. [6].
b Suspicious ultrasound: hypoechoic, microcalcifications, increased nodular vascularity, poorly demarcated; as per Cooper et al. [6].
c Nodule size: The largest diameter of the thyroid nodule measured by ultrasonography, or if ultrasound not available, then by palpation.
d Tumor size: The largest diameter of the thyroid nodule measured grossly after surgical resection.
e TFTs: Indicates which thyroid hormone values (total T3, total T4, free T3, and/or free T4) were elevated at time of presentation, as opposed to SHT or euthyroidism. Of note, for many of these cases, no mention of one
or more of these four standard thyroid hormone values was included.
















Table 3 Demographic and clinical characteristics of the
reported cases of hyperthyroid patients with
hyperfunctioning thyroid carcinoma from the literature
and the current case (n = 77)
Characteristic
Age
Mean—yr 47.0 ± 19.8*
Distribution – no. (%)
< 15 yr 6 (7.9%)
15-30 yr 10 (13.2%)
31-45 yr 20 (26.3%)
46-60 yr 15 (19.7%)
> 60 yr 25 (32.9%)




Historical – no. (%) 0 (0%)
Ultrasonographical – no. (%) 11 (36.7%)
Thyroid nodule size (via ultrasound or palpation) (cm) 4.13 ± 1.68
Thyroid carcinoma size on pathological review
Mean (cm) 2.48 ± 1.70
No. (%) with size < 1cm 8 (20.5%)
Biochemical hyperthyroidism
T3 elevated – no. (%) 39 (76.5%)
T4 elevated – no. (%) 27 (51.9%)
Subclinical hyperthyroidism – no. (%) 10 (13.0%)
Thyrotoxic symptoms – no. (%) 37 (78.7%)
Compression symptoms – no. (%) 5 (14.7%)
Thyroid scintigraphy
Technetium-99m-pertechnetate – no. (%) 16 (24.2%)
Iodine-123 or −131 – no. (%) 53 (80.3%)
Fine-needle aspiration
Benign – no. (%) 7 (30.4%)
Malignant (or suspicious findings) – no. (%) 10 (43.5%)
Follicular neoplasm – no. (%) 2 (8.7%)
Nondiagnostic sample – no. (%) 4 (17.4%)
FNA accordant with final pathological diagnosis – no. (%) 12 (60%)
FNA not accordant with final pathological diagnosis – no. (%) 9 (39.1%)
Type of thyroid carcinoma on surgical pathological review
Follicular thyroid carcinoma 28 (36.4%)
Papillary thyroid carcinoma 44 (57.1%)
Follicular variant of papillary thyroid carcinoma 8 (18.2%)
Hurthle cell carcinoma 6 (7.8%)
Insular cell carcinoma 1 (1.3%)
* Mean ± standard deviation.
no. = Number of subjects with this characteristic, % = percentage of subjects
with this characteristic.
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biochemical hyperthyroidism can be seen in patients with
malignant hyperfunctioning thyroid nodules who have lar-
ger nodules (Figure 2B).
Historical and sonographic features
We next turned our attention to high-risk historical fea-
tures and suspicious sonographic features to determine
if these were present in cases of malignant hot nodule
(Table 3). These features are described in Cooper et al.
[6] and are listed in the Tables 2 and 3 legend. None of
the 77 subjects with malignant hot nodules was noted to
have high-risk historical features. Eleven subjects (36.7%)
had suspicious features on ultrasonography, which is
likely an underestimate, as some of the more newly-
recognized high-risk sonographic features (e.g., taller
than wide on transverse view) were not utilized in the
earlier published reports. It was difficult to assess cases
for nodule growth as a risk factor for malignancy, since
the vast majority of the subjects were referred to surgery
for immediate resection. However in seven cases, nod-
ules were noted to grow over time. While an increase in
nodule size is an indication for biopsy, the specificity of
this finding for malignancy is limited, as 9-89% of benign
nodules have been shown to grow over time depending
on which definition for significant growth is used
[21,73,77,79].
Histologic subtype
The majority of malignant hot nodules were proven to
be PTC (57.1%), and of these, 18.2% were the follicular
variant of PTC (FVPTC). Follicular thyroid carcinoma
(as seen in our patient) comprised 36.4% of cases, while
Hurthle cell carcinoma was found in 7.8% of samples.
By comparison, in the U.S. National Cancer Data Base
(1985–1995), which includes histologic information on
all thyroid nodules as a group, the prevalence of PTC
was approximately 85%, FTC was 10%, and Hurthle cell
carcinoma was nearly 3% [80]. Thus, there does seem to
be a higher prevalence of both FTC and Hurthle cell
carcinoma in the hyperfunctioning thyroid carcinoma
cases.
Of note, within the 77 identified cases of malignant
hot nodule, only 23 subjects received FNA of their
thyroid nodule prior to resection. FNA enabled a pre-
operative diagnosis of thyroid carcinoma in 43.5% of
cases. However, 30.4% of subjects undergoing FNA were
erroneously characterized as having benign lesions, and
17.4% of samples were nondiagnostic. Of the subjects
with false negative biopsies, surgical pathology eventu-
ally revealed PTC in 3 cases (one of these was FVPTC),
FTC in 1 case, and Hurthle cell carcinoma in 3 cases.
Tumor size was given in only 3 instances of false nega-
tive biopsies. Two of these were of subcentimetric PTC,
Table 4 Additional cases with scintigraphic evidence suggestive of an autonomous thyroid nodule without documented hyperthyroidism (or already on
levothyroxine replacement therapy) discovered to harbor thyroid carcinoma on pathologic review






















2 44 F - 3.5 3.7 nl - - →+ Tc Benign FTC Schneider [62]
3 47 M 1.4 1 nl - 123I PTC Bourasseau [41]
4 34 F 1 1 nl - 123I “Cancer” PTC Bourasseau [41]
5 37 F 1.5 1.5 nl - 123I Nondiagnostic FTC Bourasseau [41]
6 39 M 3 nl 123I FVPTC Mizukami [46]
7 69 F Prior PTC 4 3.3 on LT4 + -
131I Hurthle Caplan [63]
8 39 M HE,PD,Cal 1.5 nl - - 123I PTC Michigishi [64]
9 65 F 4.3 nl Tc PTC Ikekubo [48]
10 37 F 2.5 nl Tc PTC Ikekubo [48]
11 39 F 3.5 nl Tc PTC Ikekubo [48]
12 38 F 4.5 nl Tc PTC Ikekubo [48]
13 35 F - 1 0.4 nl - - 123I PTC Rubenfeld [65]
14 51 M XRT “large” on LT4 -
123I FTC Nagai [50]
15 19 F 4x2→4x3 in 1 yr 4 4 nl - - 131I PTC/FTC Abdel-Razzak [66]
16 15 F - nl - - Tc PTC Scott [67]
17 27 F - 4 2.3 nl + - 131I PTC Fujimoto [68]
18 21 F 3 1 NA + + 131I PTC Becker [69]
19 23 F 1.5 1 NA - - 131I PTC Becker [69]
20 28 M 4.5 0.5 NA + - 131I PTC Molnar [70]
21 54 M 8.5 NA 131I FTC Als [58]
22 62 F NA 131I PTC Als [58]
23 61 M NA 131I FTC Als [58]
24 50 M 10 NA 131I FTC Als [58]
25 65 F 5 NA 131I FTC Als [58]
















Table 4 Additional cases with scintigraphic evidence suggestive of an autonomous thyroid nodule without documented hyperthyroidism (or already on
levothyroxine replacement therapy) discovered to harbor thyroid carcinoma on pathologic review (Continued)
27 66 F Cal nl - + Tc,131I Colloid goiter PTC Bitterman [33]
77 35 M - 5.4 0.5 Highf Hurthle Zanella [17]
Abbreviations: + = yes; - = no; Cal = microcalcifications; FNA = fine needle aspiration; FTC = follicular thyroid carcinoma; FVPTC = follicular variant of papillary thyroid carcinoma; HE = hypoechoic; 123I = Iodine-123; 131I
= Iodine-131; IV = internal vascularity; LT4 = levothyroxine; NA = not available; nl = normal; PD = poorly demarcated; PTC = papillary thyroid carcinoma; sx = symptoms; SHT = subclinical hyperthyroidism; fT3 = free
triiodothyronine; fT4 = free thyroxine; TT3 = total triiodothyronine; TT4 = total thyroxine;
99mTc = technetium-99m-pertechnetate; TFTs = thyroid function testing; U/S = ultrasound; XRT = external beam radiotherapy.
a High-risk history: ionizing radiation exposure as child/adolescent, prior personal history of thyroid cancer, and family history of thyroid cancer in one or more 1st-degree relatives; as per Cooper et al. [6].
b Suspicious ultrasound: hypoechoic, microcalcifications, increased nodular vascularity, poorly demarcated; as per Cooper et al. [6].
c Nodule size: The largest diameter of the thyroid nodule measured by ultrasonography, or if ultrasound not available, then by palpation.
d Tumor size: The largest diameter of the thyroid nodule measured grossly after surgical resection.
e TFTs: Indicates which thyroid hormone values (total T3, total T4, free T3, and/or free T4) were elevated at time of presentation, as opposed to SHT or euthyroidism. Of note, for many of these cases, no mention of one
or more of these four standard thyroid hormone values was included.
















Table 5 Demographic characteristics of patients with
solitary hyperfunctioning thyroid nodules
Author Mean age (years) Female: male (n)
Bransom [71] 49.7±13.4 33:35
Blum [72] 50.9±17.5 31:4
Burch [73] 45.8±16.8 42:13
Cappelli [11] 61.8 445:381
Giles [9] 48.5±11.4 147:29
Hamburger [21] 60±15 19:5
Iwata [74] 48.8±15.4 44:0
Landgarten [75] 49.3 106:11
Linos [76] 40 53:9
Sahin [13] 58.3±13.7 50:27
Smith [20] 34.8 24:6
Vaiana [16] 61.8 340:290
Weighted average 57.6 1.65:1
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tor leading to misdiagnosis. However, the other was a 3
cm nodule comprised wholly of Hurthle cell carcinoma.
Discussion
To our knowledge, the current data set is the largest and
most detailed to date of patients with malignant hot thy-
roid nodule. In that regard, this study complements the
informative and excellent 2012 review by Pazaitou-
Panayiotou and colleagues examining the association
of thyroid carcinoma with a broader spectrum of hy-
perthyroid states, including Graves’ disease and toxic
multinodular goiter in addition to hyperfunctioning thy-
roid nodule [81]. Of note, although it was not the focus
of the Pazaitou-Panayiotou et al. review to perform a de-
tailed analysis of the historical and clinical features of
malignant hot nodule cases, as we did here, Pazaitou-
Panayiotou and colleagues did include an evaluation of
thyroid carcinoma prevalence. The reported percentages
of thyroid carcinoma in their collected case series of pa-
tients with hot nodules, which overlapped but did not
mirror exactly those case series evaluated here and
which also included some cases of thyroid carcinoma oc-
curring in extranodular thyroid tissue, ranged between
2.5 – 12.0%. This corresponds to a weighted average of
6.9% and thus is similar to the 3.1% prevalence estimated
here. In its discussion of thyroid carcinoma in patients
with hyperfunctioning nodules, the Pazaitou-Panayiotou
et al. review also included several other important
commentaries. For instance, they draw attention to two
studies suggestive of a higher prevalence of thyroid car-
cinoma in hot nodules occurring in children [82,83],
though the latter study included children from an
iodine-deficient region. In addition, they discuss severalreports in which activating mutations of the TSH recep-
tor gene were identified within malignant hot nodules
[81].
There are several noteworthy discussion points and
implications to the findings presented here. The first re-
lates to the prevalence of malignancy within solitary hot
nodules. As mentioned, in the available surgical case
series that addressed this topic, a varied prevalence was
noted, ranging from 0 – 12.5%, with a weighted average
of 3.1%. Only a minority of the patients who underwent
surgery in those series did so because of concerning
findings from FNA, and as such, we do not believe that
the data set is biased towards cases in which a post-
operative diagnosis of malignancy was expected. We
realize that this collection of case series includes only a
small fraction of the total number of solitary hot nodules
that have occurred, and also that the vast majority of
malignant hot nodules likely have gone unreported. Fur-
thermore, it is likely that malignancy goes undiagnosed
in many cases of hot nodules treated with radioiodine,
especially those harboring microcarcinomas. Despite
these limitations, we do believe there are sufficient num-
bers of cases included among the collected 14 surgical
case series of subjects to cite the 3.1% figure as being a
fair and representative estimate of malignancy preva-
lence amongst solitary hyperfunctioning nodules. While
this 3.1% prevalence figure is low – and in fact is lower
than the estimated 5 - 15% prevalence of malignancy
among all thyroid nodules [6] – it is not trivial. Thus,
the possibility of malignancy within a hot nodule must
not be overlooked by a managing clinician, particularly if
management other than surgical resection is chosen.
Another important discussion point regards the li-
mitations resulting from the retrospective nature of this
analysis, including incomplete data and differing meth-
odology used in many of the collected case reports and
case series of malignant hot nodule. While some of the
primary sources were meticulous in their case descrip-
tions, others included less-thorough descriptions. For
example, tumor size was frequently not reported, and
thus it was unclear if a PTC tumor was simply an inci-
dental microcarcinoma embedded within a larger hot
nodule or a large, follicular variant of PTC comprising
the entirety of the nodule. While we have included some
cases in which the malignancy was a microcarcinoma
and thus of uncertain clinical significance [84], these
cases are clearly in the minority (only 8 of the 77 re-
ported tumors were less than one centimeter in size).
Other factors affecting the data set are the evolution of
technology and our understanding of risk factors for
thyroid carcinoma. For instance, thyroid ultrasound be-
gan clinical use in the late 1960s, and prior to this,
nodule size was estimated by palpation. Earlier reports
would not have commented on some of the suspicious
Figure 2 Size and biochemical assessment of hyperfunctioning thyroid nodules. (A) The mean greatest dimension of the malignant hot
thyroid nodules from our case series is compared with that from five published surgical cases series of solitary, hyperfunctioning thyroid nodules.
(B) The proportion of subjects with scintigraphically-determined hyperfunctioning thyroid carcinoma (Tables 2) who have frank biochemical
hyperthyroidism vs. subclinical hyperthyroidism, based on varying nodule size. Subjects are characterized as having nodules < 2.5 cm (A), 2.5 – 4.5
cm (B), and > 4.5 cm (C) in diameter.
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radioimmunoassays used to measure TSH have under-
gone many generations of refinement over the past sev-
eral decades, and thus the presence and degree of
hyperthyroidism may have been underestimated in ear-
lier studies.
Also worth discussing are the differential prevalences
of thyroid carcinoma histologic subtype found in hot
nodules as compared to nodules as a group. As men-
tioned, there was a much higher prevalence of both FTC
and Hurthle cell carcinoma in hot nodules (36.4% and
7.8%, respectively) as compared to in all nodules (10%
and nearly 3%, respectively). Additionally, a substantial
percentage of the PTC cases found in hot nodules were
the follicular variant. This may have bearing on the
current algorithm for evaluation of patients with thyroid
nodules as recommended in the 2009 thyroid nodule
and thyroid carcinoma management guidelines [6]. Inparticular, for those nodules found by biopsy to have fol-
licular neoplasm by histology, the guidelines recommend
consideration be made for performing an 123I thyroid
scan, if not already done, especially if the serum TSH is
in the low-normal range; if the nodule is found to be
hyperfunctioning, it can then be followed [6]. However,
the high prevalence of both FTC and FVPTC reported
for malignant hot nodules suggests that a biopsy diagno-
sis of follicular neoplasm within a hot nodule may not
be as reassuring as previously thought. Also of interest,
in a 2009 study, Sundaraiya and colleagues reported a
case of metastatic FTC occurring in the setting of thyro-
toxicosis, in which high-grade extrathyroidal uptake of
technetium-99m-pertechnetate was observed; in a litera-
ture search, they found 74 other cases of thyrotoxicosis
resulting from well-differentiated thyroid cancer meta-
static lesions, most of which demonstrated histologic
evidence of FTC [85].
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rical, biochemical or radiologic characteristics that were
assessed seems to predict malignancy in the collected
cases of hot nodules, one might ask if there is any utility
in biopsying hot nodules. Such would be a shift from the
current thyroid nodule management guidelines which
views an increased nodular radiotracer uptake pattern
as a reassuring characteristic from a cancer perspective
[6]. Given the estimated 3.1% prevalence of malignancy
within hot nodules, and also taking into account the dif-
ficulty in predicting whether a particular hot nodule is
malignant, we recommend that hot nodules that are not
treated surgically (as is an option to manage the hyper-
thyroidism) be considered for biopsy if high-risk histor-
ical and/or suspicious sonographic features are present
or if these nodules grow over time, just as is currently
recommended for nodules that are not hyperfunctioning
[6]. This should also include previously hyperfunctioning
nodules treated with radioiodine, although the known
occurrence of dystrophic calcification and cystic degen-
eration as sequelae of radioiodine ablation should be
taken into account when assessing their sonographic fea-
tures [86]. Future prospective studies could help deter-
mine if biopsying at the time of diagnosis all hot nodules
with suspicious sonographic characteristics and/or asso-
ciated high-risk historical features versus biopsying hot
nodules only if the initial sonographic characteristics
worsen over time would result in better outcomes.
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